IDE196 (LXS196)

DRUG4 trials

Sponsors

Ideaya Biosciences Inc.

Conditions

HLA-A2 negative metastatic uveal melanomaUveal Melanoma

Phase 2

(Neo)adjuvant IDE196 (Darovasertib) in Patients with Localized Ocular Melanoma

RecruitingCTIS2023-506683-14-00

Ideaya Biosciences Inc.Uveal Melanoma

Start: 2024-06-14Target: 36Updated: 2025-10-20

IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator’s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma

WithdrawnCTIS2023-506686-66-00

Ideaya Biosciences Inc.HLA-A2 negative metastatic uveal melanoma

Target: 10Updated: 2024-01-31

IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator’s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma

RecruitingCTIS2023-506686-66-01

Ideaya Biosciences Inc.HLA-A2 negative metastatic uveal melanoma

Start: 2024-10-09Target: 154Updated: 2026-01-26

Phase 3

A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OptimUM-10)

Not yet recruitingCTIS2025-522387-32-00

Ideaya Biosciences Inc.Uveal Melanoma

Target: 144Updated: 2026-01-30